GRAIL, Inc. Common Stock (GRALV) Research

GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms. Additionally, it provides DAC, a diagnostic assistance tool aimed at accelerating the diagnostic process for patients with a clinical suspicion of cancer. Beyond initial detection and diagnosis, GRAIL is also engaged in developing tests for minimal residual disease (MRD) and other post-treatment monitoring applications. Established in 2015, the company originally operated as PSC15, Inc. before rebranding as GRAIL, LLC in January 2016. Headquartered in Menlo Park, California, GRAIL, LLC functions as a subsidiary of Illumina, Inc.

Market snapshot

Symbol
GRALV
Price
$18.63
Day change
+8.19%
Market cap
$579.4M
52-week range
12.51-23.36
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • Accolade, Inc. (ACCD)
  • Apollo Endosurgery, Inc. (APEN)
  • BioDelivery Sciences International, Inc. (BDSI)
  • MultiPlan Corporation (MPLN)
  • Niagen Bioscience Inc (NAGE)
  • Regulus Therapeutics Inc. (RGLS)
  • Sage Therapeutics, Inc. (SAGE)
  • Sharecare, Inc. (SHCR)

Open GRAIL, Inc. Common Stock (GRALV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.